BACKGROUND: Patients with primary high-grade retroperitoneal soft tissue sarcomas have a 5-year disease-specific survival (DSS) of <40%. The impact of neoadjuvant therapy on histopathologic response and DSS are unknown. METHODS: From 1987 to 2007, 55 patients with primary high-grade retroperitoneal sarcoma received neoadjuvant therapy. All patients underwent surgical resection, and response was assessed histopathologically. Patients with >or=95% pathologic necrosis were classified as responders. Clinicopathologic variables were analyzed for association with DSS. Observed DSS was then compared with the Memorial Sloan-Kettering Cancer Center Sarcoma Nomogram predicted DSS. RESULTS: The median tumor size was 15 cm, and the median follow-up time for survivors was 68 months. The 5-year DSS for all 55 patients was 47% and did not significantly differ from the 37% predicted by the sarcoma nomogram for such patients (P=.44). Fourteen (25%) of the patients had >or=95% pathologic necrosis and were defined as responders; 41 (75%) were nonresponders. The 5-year DSS for responders was 83%. This was significantly better than the 5-year DSS of 34% for nonresponders (P=.002) and the 39% predicted by the sarcoma nomogram for responders (P=.018). The 34% 5-year DSS for nonresponders did not significantly differ from the 35% predicted by the sarcoma nomogram (P=.51). CONCLUSIONS: Neoadjuvant therapy was not associated with an overall improvement in DSS in patients with primary high-grade retroperitoneal sarcoma compared with the sarcoma nomogram prediction. Histopathologic response to neoadjuvant therapy was associated with a significantly improved DSS compared with nonresponders and with the sarcoma nomogram prediction for such patients. Copyright (c) 2010 American Cancer Society.
BACKGROUND:Patients with primary high-grade retroperitoneal soft tissue sarcomas have a 5-year disease-specific survival (DSS) of <40%. The impact of neoadjuvant therapy on histopathologic response and DSS are unknown. METHODS: From 1987 to 2007, 55 patients with primary high-grade retroperitoneal sarcoma received neoadjuvant therapy. All patients underwent surgical resection, and response was assessed histopathologically. Patients with >or=95% pathologic necrosis were classified as responders. Clinicopathologic variables were analyzed for association with DSS. Observed DSS was then compared with the Memorial Sloan-Kettering Cancer Center Sarcoma Nomogram predicted DSS. RESULTS: The median tumor size was 15 cm, and the median follow-up time for survivors was 68 months. The 5-year DSS for all 55 patients was 47% and did not significantly differ from the 37% predicted by the sarcoma nomogram for such patients (P=.44). Fourteen (25%) of the patients had >or=95% pathologic necrosis and were defined as responders; 41 (75%) were nonresponders. The 5-year DSS for responders was 83%. This was significantly better than the 5-year DSS of 34% for nonresponders (P=.002) and the 39% predicted by the sarcoma nomogram for responders (P=.018). The 34% 5-year DSS for nonresponders did not significantly differ from the 35% predicted by the sarcoma nomogram (P=.51). CONCLUSIONS: Neoadjuvant therapy was not associated with an overall improvement in DSS in patients with primary high-grade retroperitoneal sarcoma compared with the sarcoma nomogram prediction. Histopathologic response to neoadjuvant therapy was associated with a significantly improved DSS compared with nonresponders and with the sarcoma nomogram prediction for such patients. Copyright (c) 2010 American Cancer Society.
Authors: Martin K Angele; Markus Albertsmeier; Niclas J Prix; Peter Hohenberger; Sultan Abdel-Rahman; Nelli Dieterle; Michael Schmidt; Ulrich Mansmann; Christiane J Bruns; Rolf D Issels; Karl-Walter Jauch; Lars H Lindner Journal: Ann Surg Date: 2014-11 Impact factor: 12.969
Authors: Laura M Fayad; Charles Mugera; Theodoros Soldatos; Aaron Flammang; Filippo del Grande Journal: Skeletal Radiol Date: 2013-04-05 Impact factor: 2.199
Authors: Tara A Russell; Mark A Eckardt; Takashi Murakami; Irmina A Elliott; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Igarashi; Yungfeng Li; Joseph G Crompton; Danielle S Graham; Sarah M Dry; Nicholas Bernthal; Jane Yanagawa; Anusha Kalbasi; Noah Federman; Bartosz Chmielowski; Arun S Singh; Robert M Hoffman; Fritz C Eilber Journal: JCO Precis Oncol Date: 2017-08-04
Authors: A Montero; M Nuñez; O Hernando; E Vicente; R Ciervide; D Zucca; E Sanchez; M López; Y Quijano; M Garcia-Aranda; R Alonso; J Valero; X Chen; B Alvarez; P Fernandez-Leton; C Rubio Journal: Rep Pract Oncol Radiother Date: 2020-06-09
Authors: Thomas Schmitt; Burkhard Lehner; Bernd Kasper; Marc Bischof; Falk Roeder; Sascha Dietrich; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Gunhild Mechtersheimer; Patrick Wuchter; Anthony D Ho; Gerlinde Egerer Journal: BMC Cancer Date: 2011-12-07 Impact factor: 4.430